BPC-157 accelerates tendon healing in animal models consistently, but human RCT data remains absent as of 2026. The existing evidence — case series and open-label reports — shows positive outcomes, but cannot be separated from placebo effect or natural recovery timelines without controlled trials.
What do animal models actually demonstrate about BPC-157 and tendon repair?
Rodent and rabbit tendon transection studies consistently show accelerated collagen fibre organisation, reduced inflammatory markers, and faster tensile strength recovery with BPC-157 administration. The effect appears dose-dependent and is observed with both systemic and local injection routes. These findings are among the most replicated in the peptide preclinical literature.
The mechanism proposed involves upregulation of growth hormone receptor expression and modulation of the nitric oxide pathway, which influences vascular ingrowth into healing tendon tissue — a rate-limiting step in natural repair.
Where does the human evidence actually stand?
As of 2026, no published randomised controlled trial has evaluated BPC-157 for tendon injury in humans. Available human data consists of case reports and self-reported outcomes from open registries. These cannot establish causality. The absence of controlled human data is the single most important fact a clinician or patient needs before forming expectations.